
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-...
Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph …